Total amount: € 0,00
HOW TO ORDER
MINERVA UROLOGICA E NEFROLOGICA
A Journal on Nephrology and Urology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536
Minerva Urologica e Nefrologica 2016 Jun 29
Matrix metalloproteinase 9 and prostate-cancer risk : a meta-analysis of 1,059 participants
Fuling MA, Zhun WANG, Abdulalam ABDULARAB, Liang DAI, Yuanjie NIU, Ning JIANG ✉
Department of Urology, 2nd Hosipital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China
INTRODUCTION: Numerous studies have evaluated the association between the Matrix metalloproteinase 9(MMP-9) and prostate cancer (PCa) risk. However, these studies have yielded conflicting results.
EVIDENCE ACQUISITION: A comprehensive search was conducted through researching MEDLINE, PubMed, Web of Science, and EMBASE, and a total of 10 studies including 1,059 cases were included on the basis of inclusion criteria.
EVIDENCE SYNTHESIS: A meta-analysis was performed to obtain a summary of estimated odds ratios (ORs) and 95 % confidence intervals (CIs) of MMP-9 for PCa, with attention to study quality and publication bias. MMP-9 by IHC was significantly associated with increased diagnosis of PCa (OR=7.91; 95% CI, 5.27-11.89; P<0.00001). Subgroup-analysis showed that findings didn’t substantially change when only Caucasians or Asians (OR=5.87; 95% CI, 3.38-10.20; P<0.00001) or (OR=11.80; 95% CI, 6.60-21.08; P<0.00001) were considered. There was also no significant publication bias observed.
CONCLUSIONS: Our findings provide further evidences that the expression of MMP-9 contribute to PCa risk. MMP-9 protein overexpression was found in prostate cancers, low expression in any of the normal tissues or in benign prostatic tissue. MMP-9 is potentially an important prostate tumor marker.